Chagas Disease: American trypanosomiasis Market
Report Scope:
The current research provides a thorough overview of the CD market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.
Report Includes:
The current research provides a thorough overview of the CD market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.
Report Includes:
- An overview of the global chagas disease (T. cruzi infection) market
- Analyses of the global market trends, with historical market revenue from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the market size and revenue forecast for global chagas disease market, and corresponding market share analysis based on the product type, treatment, and region
- Overview of the significant driving trends and challenges that affect the global market and its vendor landscape
- Review of the epidemiology of chagas disease and potential of key marketed drugs and recent approvals
- Discussion of sustainability trends and factors in the chagas disease market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed
- Analysis of the competitive intelligence based on recent developments, key financials and segmental revenues, and product launch strategies
- Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses
CHAPTER 1 INTRODUCTION
Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Segmentation Breakdown
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
History
Trypanosoma Cruzi
Vector and T. cruzi
Transmission Routes
Clinical Forms
Future Perspectives
Novel Drugs
CHAPTER 4 CHAGAS DISEASE BY DRUGS
Overview
Benznidazole
Toxicity of Benznidazole
Nifurtimox
Toxicity of Nifurtimox
CHAPTER 5 CHAGAS DISEASE BY DIAGNOSIS
Overview
Serology (Antibody Detection)
Molecular Testing
CHAPTER 6 COMPETITIVE LANDSCAPE
Competitive Analysis
CHAPTER 7 COMPANY PROFILES
BAYER AG
INSUD PHARMA
CHAPTER 8 APPENDIX: ACRONYMS
Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Segmentation Breakdown
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
History
Trypanosoma Cruzi
Vector and T. cruzi
Transmission Routes
Clinical Forms
Future Perspectives
Novel Drugs
CHAPTER 4 CHAGAS DISEASE BY DRUGS
Overview
Benznidazole
Toxicity of Benznidazole
Nifurtimox
Toxicity of Nifurtimox
CHAPTER 5 CHAGAS DISEASE BY DIAGNOSIS
Overview
Serology (Antibody Detection)
Molecular Testing
CHAPTER 6 COMPETITIVE LANDSCAPE
Competitive Analysis
CHAPTER 7 COMPANY PROFILES
BAYER AG
INSUD PHARMA
CHAPTER 8 APPENDIX: ACRONYMS
LIST OF TABLES
Table 1 : Novel Drugs for Chagas Disease Treatment
Table 2 : Drugs for Chagas Disease
Table 3 : Bayer AG: Company Snapshot
Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
Table 5 : Bayer AG: News
Table 6 : Insud Pharma: Company Snapshot
Table 7 : Insud Pharma: News
Table 8 : Acronyms Used in This Report
Table 1 : Novel Drugs for Chagas Disease Treatment
Table 2 : Drugs for Chagas Disease
Table 3 : Bayer AG: Company Snapshot
Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
Table 5 : Bayer AG: News
Table 6 : Insud Pharma: Company Snapshot
Table 7 : Insud Pharma: News
Table 8 : Acronyms Used in This Report
LIST OF FIGURES
Summary Figure : Life Cycle of Trypanosoma Cruzi
Figure 1 : Bayer AG: Annual Revenue, 2021 and 2022
Figure 2 : Bayer AG: Revenue Shares, by Business Unit, 2022
Figure 3 : Bayer AG: Revenue Shares, by Region, 2022
Summary Figure : Life Cycle of Trypanosoma Cruzi
Figure 1 : Bayer AG: Annual Revenue, 2021 and 2022
Figure 2 : Bayer AG: Revenue Shares, by Business Unit, 2022
Figure 3 : Bayer AG: Revenue Shares, by Region, 2022
